The CEBPD (CCAAT/Enhancer-Binding Protein Delta) antibody is a crucial tool for studying the CEBPD protein, a member of the C/EBP family of transcription factors. CEBPD regulates genes involved in inflammation, cell differentiation, proliferation, and apoptosis. It plays roles in immune responses, metabolism, and cancer progression by binding to DNA as a homodimer or heterodimer with other C/EBP proteins. Dysregulation of CEBPD is linked to tumorigenesis, metastasis, and chemoresistance in cancers, as well as neurodegenerative and metabolic disorders.
CEBPD antibodies are widely used in techniques like Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to detect protein expression, localization, and DNA-binding activity. These antibodies help researchers investigate CEBPD's dynamic expression under stress, hormonal changes, or pathological conditions. Validated antibodies are essential for ensuring specificity, often confirmed via knockout controls or siRNA knockdown. Commercial CEBPD antibodies are typically developed in rabbits or mice using immunogenic peptide fragments. Their applications span cancer biology, immunology, and metabolic disease research, providing insights into molecular mechanisms and potential therapeutic targets. Proper validation remains critical due to potential cross-reactivity with homologous C/EBP family members.